The differential diagnostic model for serous peptidomics in HBV carriers established by MALDI-TOF-MS analysis

Clinical Biochemistry

Volumn 47, Issue 1-2, 2014, Pages 56-62

  Tian, Liyuan ^a,b   Wang, Yu ^b   Xu, Dabin ^b   Gao, Yanhong ^b   Wen, Xinyu ^b   Tian, Yaping ^b  

^a Hainan Branch of Chinese PLA General Hospital   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Asymptomatic carrier; Fibrinogen beta chain; Hepatitis B Virus; MALDI TOF MS; Nucleophosmin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; FIBRINOGEN; NUCLEOPHOSMIN;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; BETA CHAIN; CATION EXCHANGE; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HOST; HUMAN; IMMUNE RESPONSE; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; VIRUS CARRIER; WESTERN BLOTTING;

ALANINE AMINOTRANSFERASE; ALB; ALBUMIN; ALKALINE PHOSPHATASE; ALP; ALT; ASC; ASPARTATE AMINOTRANSFERASE; AST; ASYMPTOMATIC CARRIER; ASYMPTOMATIC HBV CARRIERS; AUC; FGB; FIBRINOGEN BETA CHAIN; HBV; HEPATITIS B VIRUS; MALDI-TOF-MS; MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MB-WCX; NPM; NUCLEOPHOSMIN; RECEIVER OPERATING CHARACTERISTIC; ROC; THE AREA UNDER THE ROC CURVE; WEAK CATION EXCHANGE BASED MAGNETIC BEADS;

ADULT; AGED; AMINO ACID SEQUENCE; CARRIER STATE; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84890551372     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.10.016     Document Type: Article

References (36)

1. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005, 34(Suppl. 1):S1-S3.
2. Baumert T.F., Thimme R., von Weizsacker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007, 13:82-90.
3. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-229.
4. Mohanty S.R., Kupfer S.S., Khiani V. Treatment of chronic hepatitis B. Nat Clin Pract Gastroenterol Hepatol 2006, 3:446-458.
5. Rani M., Yang B., Nesbit R. Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications. Bull World Health Organ 2009, 87:707-713.
6. Lu J., Zhou Y., Lin X., Jiang Y., Tian R., Zhang Y., et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 2009, 4:e8467.
7. Chang M.H., You S.L., Chen C.J., Liu C.J., Lee C.M., Lin S.M., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
8. Locarnini S., Zoulim F. Molecular genetics of HBV infection. Antivir Ther 2010, 15(Suppl. 3):3-14.
9. Hennig B.J., Hall A.J. Host genetic factors in hepatitis B infection, liver cancer and vaccination response: a review with a focus on Africa. Sci Total Environ 2012, 423:202-209.
10. Kao J.H. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol 2008, 2:553-562.
11. The guidelines of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2005, 13:881-891.
12. Qiu F., H-yL, X-jZ, Y-pT Optimization of magnetic beads for MALDI-TOF MS analysis. Front Biosci 2009, 14:3712-3723.
13. Pratapa P.N., Patz E.F., Hartemink A.J. Finding diagnostic biomarkers in proteomic spectra. Pac Symp Biocomput 2006, 279-290.
14. Tian L., Wang Y., Xu D., Gui J., Jia X., Tong H., et al. Serological afp/golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer 2011, 129:1923-1931.
15. Baumann H., Gauldie J. The acute phase response. Immunol Today 1994, 15:74-80.
16. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636.
17. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
18. Chisari F.V., Isogawa M., Wieland S.F. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010, 58:258-266.
19. McMahon B.J., Bulkow L.R., Singleton R.J., Williams J., Snowball M., Homan C., et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011, 54(3):801-807.
20. Paweletz C.P., Trock B., Pennanen M., Tsangaris T., Magnant C., Liotta L.A., et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001, 17:301-307.
21. Petricoin E.F., Ornstein D.K., Paweletz C.P., Ardekani A., Hackett P.S., Hitt B.A., et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002, 94:1576-1578.
22. Orvisky E., Drake S.K., Martin B.M., Abdel-Hamid M., Ressom H.W., Varghese R.S., et al. Enrichment of low molecular weight fraction of serum for ms analysis of peptides associated with hepatocellular carcinoma. Proteomics 2006, 6:2895-2902.
23. Schwegler E.E., Cazares L., Steel L.F., Adam B.L., Johnson D.A., Semmes O.J., et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005, 41:634-642.
24. Ressom H.W., Varghese R.S., Drake S.K., Hortin G.L., Abdel-Hamid M., Loffredo C.A., et al. Peak selection from MALDI-TOF mass spectra using ant colony optimization. Bioinformatics 2007, 23:619-626.
25. He Q.Y., Lau G.K., Zhou Y., Yuen S.T., Lin M.C., Kung H.F., et al. Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study. Proteomics 2003, 3:666-674.
26. Qiu F., Liu H.Y., Dong Z.N., Feng Y.J., Zhang X.J., Tian Y.P. Searching for potential ovarian cancer biomarkers with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Am J Biomed Sci 2009, 1:80-90.
27. Doolittle R.F. Fibrinogen and fibrin. Sci Am 1981, 245:126-135.
28. Liu C.Y., Sobel J.H., Weitz J.I., Kaplan K.L., Nossel H.L. Immunologic identification of the cleavage products from the A alpha- and B beta-chains in the early stages of plasmin digestion of fibrinogen. Thromb Haemost 1986, 56:100-106.
29. Skogen W.F., Senior R.M., Griffin G.L., Wilner G.D. Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood 1988, 71:1475-1479.
30. Lalla R.V., Tanzer M.L., Kreutzer D.L. Identification of a region of the fibrin molecule involved in upregulation of interleukin-8 expression from human oral squamous cell carcinoma cells. Arch Oral Biol 2003, 48:263-271.
31. Groger M., Pasteiner W., Ignatyev G., Matt U., Knapp S., Atrasheuskaya A., et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One 2009, 4:e5391.
32. Jing G.J., Xu D.H., Shi S.L., Li Q.F., Wang S.Y., Wu F.Y., et al. Aberrant expression of nuclear matrix proteins during HMBA-induced differentiation of gastric cancer cells. World J Gastroenterol 2010, 16:2176-2182.
33. Kruger T., Zentgraf H., Scheer U. Intranucleolar sites of ribosome biogenesis defined by the localization of early binding ribosomal proteins. J Cell Biol 2007, 177:573-578.
34. Maggi L.B., Kuchenruether M., Dadey D.Y., Schwope R.M., Grisendi S., Townsend R.R., et al. Nucleophosmin serves as a rate-limiting nuclear export chaperone for the mammalian ribosome. Mol Cell Biol 2008, 28:7050-7065.
35. Qi W., Shakalya K., Stejskal A., Goldman A., Beeck S., Cooke L., et al. Nsc348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene 2008, 27:4210-4220.
36. Tang J., Niu J.W., Xu D.H., Li Z.X., Li Q.F., Chen J.A. Alteration of nuclear matrix-intermediate filament system and differential expression of nuclear matrix proteins during human hepatocarcinoma cell differentiation. World J Gastroenterol 2007, 13:2791-2797.